DMII NASDAQ
Drugs Made In America Acquisition II Corp. Ordinary Shares
1W: +0.3%
1M: +0.2%
3M: +1.0%
YTD: +2.9%
$10.19
+0.00 (+0.00%)
Weekly Expected Move ±0.3%
$10
$10
$10
$10
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$649.1M
52W Range9.86-10.33
Volume17,651
Avg Volume62,485
Beta0.04
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORoger Bendelac
Employees2
SectorFinancial Services
IndustryFinancial - Conglomerates
IPO Date2025-12-04
Websitedmaacorp.com/
420 Lexington Avenue
New York, NY 10170
US
New York, NY 10170
US
954 870 3099
About Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Do Catherine | J-Other | 100,000 | — | 2025-09-26 |
| Shulgan Myron W. | J-Other | 100,000 | — | 2025-09-26 |
| Worman Glenn C. | J-Other | 100,000 | — | 2025-09-26 |